Peptide TherapeuticsPeer Reviewed
NT-proBNP serves as a prognostic marker for adverse outcomes in severe immune checkpoint inhibitor-associated myocarditis.
Authors (4)
Cheng He
Linjuan XuDepartment of Oncology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui Province, China.
Zhihong ZhangDepartment of Oncology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui Province, China.
Jiong WangDepartment of Geriatric Respiratory and Critical Care Medicine, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui Province, China.
PeerJ
Unknown
Published
Jan 01, 2025
Abstract
Abstract not available - data parsing issue resolved
Keywords
Immune checkpoint inhibitorsMyocarditisNT-proBNPPlasmapheresisPrognosis
Article Metrics
Sourcepubmed
Related Research
Explore more articles in this research category to discover related studies and findings.